immunotherapy / eff Cancer Research Results

immuno, immunotherapy: Click to Expand ⟱
Features: 
Immunotherapy is not one drug class. It includes:
-Immune checkpoint inhibitors (PD-1, PD-L1, CTLA-4)
-CAR-T therapies
-Monoclonal antibodies
-Cytokine therapies (IL-2, IFN-α)
-Cancer vaccines
-Bispecific T-cell engagers
PD-1 blockade antibody therapy is one of the cornerstone approaches in modern cancer immunotherapy.
Under normal physiological conditions, when PD-1 binds to its ligands (PD-L1 or PD-L2) on other cells, it functions as a "checkpoint" to reduce overly active T cell responses and prevent autoimmunity.
PD-1 blockade therapies involve monoclonal antibodies that target either PD-1 or its ligand PD-L1.
• By blocking the interaction between PD-1 and its ligands, these antibodies effectively release the "brakes" on T cells.
• The re-activated T cells can then recognize and destroy cancer cells more efficiently.

Immunotherapy Class Example Agents Primary Target Core Mechanism Interaction Considerations Net Effect
PD-1 inhibitors Nivolumab, Pembrolizumab PD-1 receptor on T cells Blocks inhibitory PD-1 signaling → restores cytotoxic T-cell activity High-dose steroids or strong immunosuppressants may blunt effect; autoimmune risk ↑ Anti-tumor immune activation
PD-L1 inhibitors Atezolizumab, Durvalumab PD-L1 on tumor/immune cells Prevents PD-L1 from engaging PD-1 → enhances T-cell response Similar immune-related adverse event (irAE) profile as PD-1 inhibitors ↑ Immune activation
CTLA-4 inhibitors Ipilimumab CTLA-4 checkpoint Enhances early T-cell priming in lymph nodes Higher autoimmune toxicity risk vs PD-1 class ↑ T-cell priming
CAR-T therapy CD19 CAR-T products Tumor antigen (e.g., CD19) Genetically engineered T cells directly target tumor cells Risk of cytokine release syndrome (CRS) and neurotoxicity Direct immune-mediated tumor killing
Monoclonal antibodies (non-checkpoint) Trastuzumab, Rituximab Specific tumor antigens Antibody-dependent cellular cytotoxicity (ADCC) or receptor blockade Combination with chemo common; immune activation depends on Fc engagement Targeted immune-mediated killing
Cytokine therapy IL-2, IFN-α Immune activation pathways Stimulates T-cell and NK cell proliferation High systemic toxicity; rarely used now vs checkpoint inhibitors Broad immune stimulation
Cancer vaccines mRNA or peptide-based Tumor antigens Induces tumor-specific immune memory Often combined with checkpoint blockade Adaptive immune priming
Bispecific T-cell engagers Blinatumomab CD3 + tumor antigen Bridges T cells directly to tumor cells CRS risk; continuous infusion in some protocols Direct T-cell redirection


eff, efficacy: Click to Expand ⟱
Source:
Type:
Power to enhance an anti cancer effect
Scientific Papers found: Click to Expand⟱
5350- Akk,  immuno,    Enhancing Immune Response in Immunotherapy-Resistant Melanoma Through Fecal Microbiota Transplantation: A Systematic Review
eff↑,
5349- Akk,  immuno,    Improved survival in advanced melanoma patients treated with fecal microbiota transplantation using healthy donor stool in combination with anti-PD1: final results of the MIMic phase 1 trial
- Case Report, Melanoma, NA
eff↑, OS↑, eff↑,
5348- Akk,  immuno,    Gut Microbiota Modulation through Akkermansia spp. Supplementation Increases CAR T-cell Potency
- Human, Var, NA
other↑, eff↑,
5347- Akk,  immuno,    Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer
- Human, NSCLC, NA
eff↑,
5346- Akk,  immuno,    Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
- in-vivo, Var, NA
eff↑,
1360- Ash,  immuno,    Withaferin A Increases the Effectiveness of Immune Checkpoint Blocker for the Treatment of Non-Small Cell Lung Cancer
- in-vitro, Lung, H1650 - in-vitro, Lung, A549 - in-vitro, CRC, HCT116 - in-vitro, BC, MDA-MB-231 - in-vivo, NA, NA
PD-L1↑, eff↓, ROS↑, ER Stress↑, Apoptosis↑, BAX↑, Bak↑, BAD↑, Bcl-2↓, XIAP↓, survivin↓, cl‑PARP↑, CHOP↑, p‑eIF2α↑, ICD↑, eff↑,
5568- B-Gluc,  immuno,    Beta-glucans in oncology: revolutionizing treatment with immune power & tumor targeting
- Review, Var, NA
TNF-α↓, IL6↓, NF-kB↓, PD-L1↓, Imm↑, BAX↑, Bcl-2↓, TumCCA↑, angioG↓, VEGF↓, MMPs↓, OS↑, chemoP↑, eff↑, BioAv↑,
5516- BEV,  immuno,  Chemo,    Targeting vascular normalization: a promising strategy to improve immune–vascular crosstalk in cancer immunotherapy
- Review, Var, NA
OS↑, eff↑,
5594- BEV,  immuno,    Serum VEGF-A as a biomarker for the addition of bevacizumab to chemo-immunotherapy in metastatic NSCLC
- Human, NSCLC, NA
eff↑,
5628- Bif,  immuno,    Bifidobacterium modulation of tumor immunotherapy and its mechanism
- Review, Var, NA
Imm↑, Risk↓, GutMicro↑, AntiTum↑, OS↑, selectivity↑, eff↑,
5625- Bif,  immuno,    The gut microbiome and cancer response to immune checkpoint inhibitors
- Review, Var, NA
eff↑, eff↓,
6019- CGA,  immuno,    Combination immunotherapy of chlorogenic acid liposomes modified with sialic acid and PD-1 blockers effectively enhances the anti-tumor immune response and therapeutic effects
- in-vivo, Melanoma, NA
eff↑, Dose↝, AntiTum↑, eff↑,
1244- CGA,  immuno,    Cancer Differentiation Inducer Chlorogenic Acid Suppresses PD-L1 Expression and Boosts Antitumor Immunity of PD-1 Antibody
- in-vivo, NA, NA
PD-L1↓, T-Cell↑, eff↑,
5985- Chit,  immuno,    Immunomodulatory potential of chitosan-based materials for cancer therapy: a systematic review of in vitro, in vivo and clinical studies.
- Review, Var, NA
TumCP↓, TumW↓, OS↑, eff↑,
4914- DSF,  immuno,    Disulfiram and cancer immunotherapy: Advanced nano-delivery systems and potential therapeutic strategies
- Review, Var, NA
AntiTum↑, eff↑, ALDH↓, Dose↝, RadioS↑, angioG↓, TumMeta↓, BioAv↝, ROS↑, DNAdam↑, P-gp↓, CSCs↓, EMT↓, Imm↑, SOD↓, MAPK↓, NF-kB↓, ChemoSen↑, eff↑, toxicity↝, BioAv↑, *Inflam↓, Sepsis↓,
1041- Lyco,  immuno,    Lycopene improves the efficiency of anti-PD-1 therapy via activating IFN signaling of lung cancer cells
- in-vivo, Lung, NA
TumVol↓, TumW↓, eff↑, IL1↑, IFN-γ↑, IL4↓, IL10↓,
1043- MET,  immuno,    Metformin reduces PD-L1 on tumor cells and enhances the anti-tumor immune response generated by vaccine immunotherapy
- in-vitro, NA, NA
eff↑, PD-L1↓, Ki-67↑, TIM-3↑, L-sel↑,
537- MF,  immuno,    Integrating electromagnetic cancer stress with immunotherapy: a therapeutic paradigm
- Review, Var, NA
Apoptosis↑, ROS↑, TumAuto↑, Ca+2↑, ATP↓, eff↑, eff↑,
516- MFrot,  immuno,  MF,    Anti-tumor effect of innovative tumor treatment device OM-100 through enhancing anti-PD-1 immunotherapy in glioblastoma growth
- vitro+vivo, GBM, U87MG
TumCP↓, Apoptosis↑, TumCMig↓, ROS↑, PD-L1↑, TumVol↓, eff↑, *toxicity∅, eff↑, *toxicity∅, Dose↝, tumCV↓, TumCI↓,
5602- NaHCO3,  immuno,    Immunotherapy Enhancement by Targeting Extracellular Tumor pH in Triple-Negative Breast Cancer Mouse Model
- in-vivo, BC, 4T1
eff↑, TumCG↓, OS↑, e-pH↑, IFN-γ↑, IL2↑, IL12↑, Dose↝, PD-L1↓,
5603- NaHCO3,  immuno,    Acidosis-mediated increase in IFN-γ-induced PD-L1 expression on cancer cells as an immune escape mechanism in solid tumors
- in-vitro, BC, MCF-7 - in-vitro, PC, MIA PaCa-2 - in-vitro, GBM, U87MG
eff↑, e-pH↑, PD-L1↓,
5612- NaHCO3,  immuno,    Neutralization of tumor acidity improves anti-tumor responses to immunotherapies
- vitro+vivo, Var, B16-F10
Imm↑, eff↑, e-pH↑, TumCG↓, TumMeta↓, eff↑,
5615- NaHCO3,  immuno,    pH-Responsive Nanoparticles for Cancer Immunotherapy: A Brief Review
- Review, Var, NA
eff↑, eff↑, pH↑,
4690- PTS,  immuno,    Pterostilbene: Mechanisms of its action as oncostatic agent in cell models and in vivo studies
- Review, Var, NA
eff↑, Half-Life↑, TumCG↓, TumMeta↓, angioG↓, CSCs↓, Apoptosis↑, eff↑, CD44↓, CD24↓,
4896- Sper,  immuno,    Spermidine potentiates anti-tumor immune responses and immunotherapy sensitivity in breast cancer
- vitro+vivo, BC, NA
eff↑, AntiTum↑,
4893- Sper,  immuno,    Chemoproteomic Identification of Spermidine-Binding Proteins and Antitumor-Immunity Activators
- in-vitro, Var, NA
*mt-FAO↑, eff↑,
3121- VitC,  immuno,    Ascorbic acid induced TET2 enzyme activation enhances cancer immunotherapy efficacy in renal cell carcinoma
- in-vivo, RCC, A498 - in-vitro, RCC, 786-O
TET2↑, eff↑, eff↑,

Showing Research Papers: 1 to 27 of 27

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 27

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

ICD↑, 1,   ROS↑, 4,   SOD↓, 1,  

Mitochondria & Bioenergetics ⓘ

ATP↓, 1,   XIAP↓, 1,  

Cell Death ⓘ

Apoptosis↑, 4,   BAD↑, 1,   Bak↑, 1,   BAX↑, 2,   Bcl-2↓, 2,   MAPK↓, 1,   survivin↓, 1,  

Transcription & Epigenetics ⓘ

other↑, 1,   tumCV↓, 1,  

Protein Folding & ER Stress ⓘ

CHOP↑, 1,   p‑eIF2α↑, 1,   ER Stress↑, 1,  

Autophagy & Lysosomes ⓘ

TumAuto↑, 1,  

DNA Damage & Repair ⓘ

DNAdam↑, 1,   cl‑PARP↑, 1,  

Cell Cycle & Senescence ⓘ

TumCCA↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

ALDH↓, 1,   CD24↓, 1,   CD44↓, 1,   CSCs↓, 2,   EMT↓, 1,   TumCG↓, 3,  

Migration ⓘ

Ca+2↑, 1,   Ki-67↑, 1,   L-sel↑, 1,   MMPs↓, 1,   TumCI↓, 1,   TumCMig↓, 1,   TumCP↓, 2,   TumMeta↓, 3,  

Angiogenesis & Vasculature ⓘ

angioG↓, 3,   VEGF↓, 1,  

Barriers & Transport ⓘ

P-gp↓, 1,  

Immune & Inflammatory Signaling ⓘ

IFN-γ↑, 2,   IL1↑, 1,   IL10↓, 1,   IL12↑, 1,   IL2↑, 1,   IL4↓, 1,   IL6↓, 1,   Imm↑, 4,   NF-kB↓, 2,   PD-L1↓, 5,   PD-L1↑, 2,   T-Cell↑, 1,   TNF-α↓, 1,  

Cellular Microenvironment ⓘ

pH↑, 1,   e-pH↑, 3,   TIM-3↑, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↑, 2,   BioAv↝, 1,   ChemoSen↑, 1,   Dose↝, 4,   eff↓, 2,   eff↑, 36,   Half-Life↑, 1,   RadioS↑, 1,   selectivity↑, 1,   TET2↑, 1,  

Clinical Biomarkers ⓘ

GutMicro↑, 1,   IL6↓, 1,   Ki-67↑, 1,   PD-L1↓, 5,   PD-L1↑, 2,  

Functional Outcomes ⓘ

AntiTum↑, 4,   chemoP↑, 1,   OS↑, 6,   Risk↓, 1,   toxicity↝, 1,   TumVol↓, 2,   TumW↓, 2,  

Infection & Microbiome ⓘ

Sepsis↓, 1,  
Total Targets: 77

Pathway results for Effect on Normal Cells:


Core Metabolism/Glycolysis ⓘ

mt-FAO↑, 1,  

Immune & Inflammatory Signaling ⓘ

Inflam↓, 1,  

Functional Outcomes ⓘ

toxicity∅, 2,  
Total Targets: 3

Scientific Paper Hit Count for: eff, efficacy
27 immunotherapy
5 Akkermansia
4 Bicarbonate(Sodium)
2 Bevacizumab (brand Avastin)
2 Bifidobacterium
2 Chlorogenic acid
2 Magnetic Fields
2 Spermidine
1 Ashwagandha(Withaferin A)
1 beta-glucans
1 Chemotherapy
1 chitosan
1 Disulfiram
1 Lycopene
1 Metformin
1 Magnetic Field Rotating
1 Pterostilbene
1 Vitamin C (Ascorbic Acid)
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:207  Target#:961  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page